BioMarin Pharma (BMRN) Tops Q3 EPS by 23c; offers guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.53 +0.15%
Revenue Growth %: +32.7%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +32.7%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.46, $0.23 better than the analyst estimate of $0.23. Revenue for the quarter came in at $581.3 million versus the consensus estimate of $607.5 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.90-$2.05, versus the consensus of $2.19. BioMarin Pharma sees FY2023 revenue of $2390-2470 million, versus the consensus of $2449 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
